![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260916_Remepy_Leadership_Tracker-768x432.png\"){kind=tracking}
<\/p>\n<\/p>\n
Company:<\/strong> Remepy · Event Type:<\/strong> Executive Appointment · New CXO:<\/strong> Eran Harary, M.D. · Context:<\/strong> Joins from Teva ahead of planned global Phase III development of Hybridopa for Parkinson’s disease · Date:<\/strong> September 16, 2026<\/p>\n Remepy appointed Eran Harary, M.D., chief medical officer effective October 1, 2026. He joins from Teva, where he most recently led early clinical development and previously held global specialty R&D and neurology and psychiatry leadership roles. The appointment comes after Remepy’s $36 million Series A and before the company’s stated plan to begin global Phase III development of Hybridopa for Parkinson’s disease in the fourth quarter of 2026. The role strengthens clinical and regulatory capacity, but the specific appointment reason, predecessor, whether the CMO post is newly created, and any continuing Teva role were not disclosed.<\/p>\n The company announced the appointment on September 16 and updated its leadership page to list Harary as CMO. His remit covers clinical-development strategy, trial execution, and medical and regulatory engagement across the pipeline. Remepy highlighted his experience taking long-acting neuropsychiatry products through development and approval, including work on UZEDY and other movement-disorder programs. No predecessor, associated departure, compensation, board role or employment-transition details were identified.<\/p>\n Hybridopa’s Phase IIa evidence was generated in a small, three-week randomized pilot in levodopa-treated patients. Reported improvements and neuroimaging associations justify larger testing but do not separate expectancy, engagement, multiplicity and durability effects with the precision required for approval. Phase III will need robust blinding, prespecified engagement handling, device and software change control, data-security governance, adherence measurement and clinically meaningful motor and non-motor endpoints.<\/p>\n Bull case:<\/strong> Remepy is installing late-stage drug-development leadership for a program approaching pivotal testing. This is supported by the stated Phase III timing, the August financing, and Harary’s clinical, regulatory and neuroscience background. A CMO can centralize protocol governance, safety oversight, regulator interaction and evidence planning across the drug and software components.<\/p>\n Bear case:<\/strong> The company has not disclosed Phase III authorization, a trial registration, finalized endpoints or regulator feedback. The appointment therefore does not establish readiness to start or a specific regulatory path. It may also represent ordinary organizational maturation rather than a strategy change, since Remepy already has a chief clinical development officer and other therapeutic leaders; overlap could create ambiguous accountability that the disclosure does not resolve.<\/p>\n Remepy develops drug-software combinations that pair established pharmacology with adaptive digital interventions. Hybridopa combines immediate-release levodopa and carbidopa with DopApp, a mobile protocol delivering personalized motor, cognitive, behavioral, speech and rehabilitative exercises. Levodopa replenishes dopamine synthesis, while carbidopa limits peripheral levodopa metabolism. Hybridopa is investigational and unapproved. A reported Phase IIa pilot randomized approximately 41 levodopa-treated patients for three weeks; larger and longer studies are required to establish durable clinical benefit and safety.<\/p>\n This is a neutral, moderate-importance leadership signal. Harary adds directly relevant neuroscience, clinical-development and regulatory experience at a transition from pilot evidence to planned pivotal testing. The most defensible interpretation is capability expansion, not a strategic pivot or efficacy signal. The proposition that the appointment improves approval probability is not supportable without operational and clinical evidence.<\/p>\n Importance:<\/strong> 3\/5 · Direction:<\/strong> Neutral · Confidence:<\/strong> High on facts (the appointment, effective date, current leadership listing, prior roles and disclosed development timing are confirmed); low-to-moderate on interpretation (the role’s predecessor status, governance, detailed reason, compensation and effect on execution are undisclosed).<\/p>\n","protected":false},"excerpt":{"rendered":" Remepy appointed Eran Harary, M.D., chief medical officer effective October 1, 2026. He joins from Teva, where he most recently led early clinical development and previously held global specialty R&D and neurology and psychiatry…<\/p>\n","protected":false},"author":1,"featured_media":3206,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,196],"tags":[778,777],"class_list":["post-3198","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-leadership-tracker","tag-parkinsons-disease-2","tag-remepy"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3198"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3198\/revisions"}],"predecessor-version":[{"id":3217,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3198\/revisions\/3217"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3206"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
\n Factor<\/th>\n Assessment<\/th>\n<\/tr>\n \n Effective date<\/td>\n Harary becomes chief medical officer on October 1, 2026.<\/td>\n<\/tr>\n \n Predecessor and reason<\/td>\n No predecessor or departure was disclosed; whether the role is newly created is also undisclosed.<\/td>\n<\/tr>\n \n Continuity<\/td>\n Remepy’s existing chief clinical development officer remains listed; reporting lines were not described.<\/td>\n<\/tr>\n \n Milestone timing<\/td>\n The appointment follows a $36 million Series A and precedes a stated Q4 2026 Phase III start.<\/td>\n<\/tr>\n \n Falsification test<\/td>\n The execution thesis weakens if Phase III authorization slips without explanation, governance remains unclear, or pivotal design fails to address engagement, durability and software-control risks.<\/td>\n<\/tr>\n<\/table>\n InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n